Related references
Note: Only part of the references are listed.Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials
Masayoshi Harigai et al.
MODERN RHEUMATOLOGY (2020)
Smoking cessation is associated with lower disease activity and predicts cardiovascular risk reduction in rheumatoid arthritis patients
Ida K. Roelsgaard et al.
RHEUMATOLOGY (2020)
Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment
Josef S. Smolen et al.
JOURNAL OF RHEUMATOLOGY (2019)
Clinical effectiveness and long-term retention of abatacept in elderly rheumatoid arthritis patients: Results from a multicenter registry system
Nobunori Takahashi et al.
MODERN RHEUMATOLOGY (2019)
Concomitant methotrexate has little effect on clinical outcomes of abatacept in rheumatoid arthritis: a propensity score matching analysis
Nobunori Takahashi et al.
CLINICAL RHEUMATOLOGY (2019)
PRACTICAL MANAGEMENT of patients on Janus kinase inhibitor (JAKi) therapy Practical fact sheets drawn up by the Rheumatism and inflammation (CRI) a ground endorsed by the french Society for Rheumatology (SFR)
Christophe Richez et al.
JOINT BONE SPINE (2019)
Smoking Is Associated with Higher Disease Activity in Rheumatoid Arthritis: A Longitudinal Study Controlling for Time-varying Covariates
Milena A. Gianfrancesco et al.
JOURNAL OF RHEUMATOLOGY (2019)
Clinical significance of Janus Kinase inhibitor selectivity
Ernest H. Choy
RHEUMATOLOGY (2019)
Risk for Herpes Zoster in Tofacitinib-Treated Rheumatoid Arthritis Patients With and Without Concomitant Methotrexate and Glucocorticoids
Jeffrey R. Curtis et al.
ARTHRITIS CARE & RESEARCH (2019)
Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis: A 52-week, randomized, single-blind, extension study
Yoshiya Tanaka et al.
MODERN RHEUMATOLOGY (2018)
Efficacy and safety of baricitinib in Japanese patients with rheumatoid arthritis: Subgroup analyses of four multinational phase 3 randomized trials
Yoshiya Tanaka et al.
MODERN RHEUMATOLOGY (2018)
Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis
Mark C. Genovese et al.
RHEUMATOLOGY (2018)
A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis population
Alan J. Kivitz et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2018)
Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study
Maxime Dougados et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
The emerging safety profile of JAK inhibitors in rheumatic disease
Kevin L. Winthrop
NATURE REVIEWS RHEUMATOLOGY (2017)
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
Peter C. Taylor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment
Roy Fleischmann et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis
Roy Fleischmann et al.
RMD OPEN (2017)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Progress in understanding the safety and efficacy of Janus kinase inhibitors for treatment of rheumatoid arthritis
Shigeru Iwata et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2016)
Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis
Masayoshi Harigai et al.
MODERN RHEUMATOLOGY (2016)
Baricitinib in Patients with Refractory Rheumatoid Arthritis
Mark C. Genovese et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Jasvinder A. Singh et al.
ARTHRITIS & RHEUMATOLOGY (2016)
Belimumab for Systemic Lupus Erythematosus: A Cochrane Systematic Review and MetaAnalysis
Jasvinder A. Singh et al.
ARTHRITIS & RHEUMATOLOGY (2015)
Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate
Edward C. Keystone et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Use of a 12-week observational period for predicting low disease activity at 52 weeks in RA patients treated with abatacept: a retrospective observational study based on data from a Japanese multicentre registry study
Nobunori Takahashi et al.
RHEUMATOLOGY (2015)
Effectiveness and Safety of Tocilizumab: Postmarketing Surveillance of 7901 Patients with Rheumatoid Arthritis in Japan
Takao Koike et al.
JOURNAL OF RHEUMATOLOGY (2014)
Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: Postmarketing surveillance report of 7740 patients
Takao Koike et al.
MODERN RHEUMATOLOGY (2014)
Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)
Maxime Dougados et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
MECHANISMS OF DISEASE JAKs and STATs in Immunity, Immunodeficiency, and Cancer
John J. O'Shea et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Study protocol of a multicenter registry of patients with rheumatoid arthritis starting biologic therapy in Japan: Tsurumai Biologics Communication Registry (TBCR) Study
Toshihisa Kojima et al.
MODERN RHEUMATOLOGY (2012)
Clinical efficacy of abatacept in Japanese rheumatoid arthritis patients
Nobunori Takahashi et al.
Modern Rheumatology (2012)
2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative
Daniel Aletaha et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050
Jordan S. Fridman et al.
JOURNAL OF IMMUNOLOGY (2010)
Differences between the Health Assessment Questionnaire Disability Index (HAQ-DI) and the modified HAQ (mHAQ) score before and after infliximab treatment in patients with rheumatoid arthritis
Hayato Nagasawa et al.
MODERN RHEUMATOLOGY (2010)
Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor
Jean-Michel Dayer et al.
RHEUMATOLOGY (2010)
Epidemiology of Herpes Zoster and Its Relationship to Varicella in Japan: A 10-Year Survey of 48,388 Herpes Zoster Cases in Miyazaki Prefecture
Nozomu Toyama et al.
JOURNAL OF MEDICAL VIROLOGY (2009)
Disease Activity Score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in Japan
Toshihiro Matsui et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Comparison of Disease Activity Score (DAS) 28-erythrocyte sedimentation rate and DAS28-C-reactive protein threshold values
Eisuke Inoue et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Validation of a Japanese version of the Stanford health assessment questionnaire in 3,763 patients with rheumatoid arthritis
Y Matsuda et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2003)
Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases
H Ohnishi et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2002)
Share Paper
